Following Pfizer''s announcement last month that it has agreed to acquire rival big pharma Pharmacia, Oxford GlycoSciences chief financial officer Stephen Parker said last week that his company is holding out hope that its proteomics relationship with Pfizer emerges unscathed.

"At the moment at least, it doesn''t seem to be getting in the way," he told ProteoMonitor in reference to Pfizer''s pending acquisition. "Amazingly, they don''t even seem to be distracted."